Inhibiting Tumour Cell Attachment in Breast Cancer Spread to Bone

Grant number: 509131 | Funding period: 2008 - 2010

Completed

Abstract

There are limited effective treatments for advanced breast cancer. The project investigates the role of a protein called integrin beta3 in the spread of breast tumours to bone, the most common site of secondary tumour formation (metastasis) in breast cancer patients. We will determine if the presence of integrin beta3 in breast tumours identifies patients at risk of developing bone metastases and test novel drugs against integrin beta3 in mice.

Related publications (2)

Tumour but not stromal expression of β 3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer

RZ Carter, KC Micocci, A Natoli, RP Redvers, S Paquet-Fifield, ACBM Martin, D Denoyer, X Ling, SH Kim, R Tomasin, H Selistre-De-Araújo, RL Anderson, N Pouliot

2015-04-01

Although many preclinical studies have implicated β3 integrin receptors (αvβ3 and αIIbβ3) in cancer progression, β3 inhibitors hav..

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer

CN Johnstone, YE Smith, Y Cao, AD Burrows, RSN Cross, X Ling, RP Redvers, JP Doherty, BL Eckhardt, AL Natoli, CM Restall, E Lucas, HB Pearson, S Deb, KL Britt, A Rizzitelli, J Li, JH Harmey, N Pouliot, RL Anderson

2015-03-01

The translation of basic research into improved therapies for breast cancer patients requires relevant preclinical models that inc..

University of Melbourne Researchers

Robin Anderson